The regulator said it is currently seeking nominations of individuals with “technical and scientific expertise from diverse disciplines and backgrounds” who can advise it on the benefits, risks, and clinical outcomes associated with the use of digital health technologies (DHTs).
The committee will consist of nine voting members, including the chair, and could include representatives from industry, consumer organisations, and the medical profession. It is due to be fully operational in 2024, said the FDA, which will accept nominations through to 11th December.
